Cognizant’s Shared Investigator Platform (SIP) has integrated with Oracle Health Sciences. Cognizant and Oracle have combined the SIP solution and study startup offerings to address site challenges and aim to deliver value in the initialization of studies, collaboration, and management.
“Being able to stay connected, reduce administrative work, and stand-up clinical trials quickly is paramount, especially as the world faces the pandemic and must maneuver around social distancing guidelines,” said Srinivas Shankar, Global Head of Life Sciences, Cognizant. “Since 2016, Cognizant’s Shared Investigator Platform has over 130,000 users across 100 countries. This digital solution, in collaboration with Oracle, is helping bridge digital technology and life sciences.”
For more information, click here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.